Business context and reporting period
BeyondSpring Inc. filed this Form 8-K to report the September 30, 2026 closing of a previously announced sale and collaboration. The filing also refers to unaudited pro forma financial information based on a June 30, 2026 balance sheet and statements of operations for the six months ended June 30, 2026 and years ended December 31, 2025 and 2024; the pro forma figures are not included in the supplied filing text.
Transaction and key financial implications
- BeyondSpring sold and transferred all issued shares of BeyondSpring Ltd., its wholly owned subsidiary that indirectly held interests in Dalian Wanchunbulin Pharmaceuticals Ltd. (Bulin), to Biolin Investment Limited.
- No cash consideration was paid or payable at closing. The consideration was the investor’s obligation to conduct and complete the China portion of the DUBLIN-4 Phase 3 trial and cause Bulin to take certain related actions.
- BeyondSpring will have access to clinical data generated by the China portion of the trial.
- The filing text does not provide clear values for revenue, profit or loss, cash flow, margins, debt, liquidity, or the financial effects of the sale. It identifies pro forma statements in Exhibit 99.1 but does not reproduce their figures.
Material changes versus prior periods
The transaction removes the indirect Bulin interests held through BeyondSpring Ltd. from BeyondSpring’s ownership structure. The filing provides no comparable financial amounts or quantified changes versus prior periods.
Outlook, commentary and risks
The collaboration relates to completing the China portion of DUBLIN-4, which evaluates plinabulin with docetaxel for advanced or metastatic non-squamous non-small cell lung cancer after prior anti-PD-(L)1 therapy and platinum-based chemotherapy. No financial guidance or quantified outlook is provided. BeyondSpring cautions that actual results may differ from the pro forma presentation and that differences could be material.
Important facts for investors to verify
- Review Exhibit 99.1 for the pro forma balance sheet, statements of operations, adjustments, and transaction accounting.
- Review the Share Purchase and Collaboration Agreement for the investor’s trial-completion obligations, conditions, and any other material terms.
- Monitor progress and completion of the China portion of DUBLIN-4 and the availability of resulting clinical data to BeyondSpring.
- Assess the effect of the divestiture on BeyondSpring’s future financial statements and operating structure.